Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years

NCT02269475 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02269475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
April 30, 2015
Enrollment
1,369 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

healthy japanese children age 7 years through 18 years